High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma.

Aim: The aim of this study was to investigate the relationship of pretreatment serum IL-10 (sIL-10) levels with known prognostic factors and with failure-free survival (FFS) in patients with Hodgkin's lymphoma (HL).

Patients And Methods: Interleukin-10 (IL-10) levels were measured in the sera of 36 untreated patients with HL and were subsequently correlated with clinical and laboratory prognostic parameters as well as with FFS.

Results: 36 untreated HL patients (21 men, median age 31 (18-62) years) were studied.